IV iron formulations linked to varying risks for anaphylaxis in older adults: Study

New Jersey: The rates of anaphylaxis after administration of all IV iron products are very low but are 3- to 8-fold higher for iron dextran and ferumoxytol than for iron sucrose, a recent study has found. The study was published in the Annals of Internal Medicine on 29 March 2022. 

The study was conducted by Chintan V. Dave and the team from New Jersey conducted the study with an aim to compare risks for anaphylaxis among 5 IV iron products that are used frequently in a retrospective cohort study using a target trial emulation framework.

The study was done with Medicare fee-for-service data with Part D coverage between July 2013 and December 2018 and included older adults receiving their first administration of IV iron.

The occurrence of anaphylaxis within 1 day of IV iron administration, ascertained using a validated case definition was the primary outcome. Using the inverse probability of treatment weighting, analysis was adjusted for 40 baseline covariates. The researchers computed the adjusted incidence rates (IRs) for anaphylaxis per 10 000 first administrations and odds ratios.